Study of Cingal® for Symptomatic Relief of Osteoarthritis of Hip Joint
Study Details
Study Description
Brief Summary
This Trial will obtain clinical data to support an expanded indication for a single injection of Cingal® used for the symptomatic relief of osteoarthritis in the hip joint.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
CINGAL® is a chemically cross-linked sodium hyaluronate combined with Triamcinolone Hexacetonide supplied as a 4-mL unit dose in a 5-mL glass syringe. Cingal will be injected into the intraarticular (IA) space of the index hip using an 18-21-gauge needle. It is used for the symptomatic relief of osteoarthritis in the hip joint.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Cingal
|
Device: Cingal
CINGAL® is a chemically cross-linked sodium hyaluronate combined with Triamcinolone Hexacetonide supplied as a 4-mL unit dose in a 5-mL glass syringe.
|
Outcome Measures
Primary Outcome Measures
- Primary Endpoint [6 months]
Reduction of index hip Numerical Rating Scale (NRS) pain (0 to 10 with 0 No Pain and 10 Worst Pain) on walking from baseline to 6 Months post injection.
Eligibility Criteria
Criteria
Screening Inclusion Criteria:
-
Age 18 years or older
-
Body Mass Index (BMI) ≤ 35 kg/m2
-
Diagnosis of symptomatic osteoarthritic joint in the index hip (Kellgren-Lawrence grade I to III) to be treated with CINGAL injection.
-
Failed conservative treatment for joint osteoarthritis.
-
NRS on walking ≥4 and ≤ 9 in index hip.
-
Subject must be willing to abstain from other treatments of the index hip for the duration of the study.
-
Subject is willing to discontinue all analgesics including NSAIDs, except acetaminophen/paracetamol, at least seven days before the treatment injection and through the completion of the study.
-
Subject is willing to use only acetaminophen/paracetamol (up to a maximum of 4.0 grams per day per the package insert) for the treatment of joint pain for the duration of the study. At least forty-eight hours prior to the Baseline Visit and each follow-up assessment, the subject is willing to discontinue use of acetaminophen/paracetamol.
-
Subject is willing to maintain a stable dose of oral glucosamine and/or chondroitin sulfate products throughout the study, if taken prior to signing the informed consent form (ICF).
-
Able and willing to provide signed informed consent.
Baseline Inclusion Criteria
- NRS pain on walking ≥4 and ≤ 9 in index hip
Screening Exclusion Criteria:
-
History of hypersensitivity to any of the ingredients in the hyaluronan or corticosteroids
-
Infection or skin disease in the area of the injection site or hip joint
-
NRS pain on walking > 3 the contralateral hip.
-
NRS pain on walking > 3 in the ipsilateral knee or ankle joints.
-
Subject received an injection of Hyaluronic Acid (HA) and/or steroid in either joint within 6 months of signing the informed consent form (ICF). A subject will be excluded if they are planning to receive an HA or steroid injection (other than the study injection) in either joint during the course of this study.
-
Known inflammatory or autoimmune disorders (including rheumatoid arthritis, gout), or other pre-existing medical conditions that, in the opinion of the investigator, could impact treatment of the hip joint or affect the ability of the subject to accurately complete the study questionnaires and comply with the study requirements.
-
Subject is taking medications at the time of signing the ICF which could interfere with the treatment procedure, healing and/or assessments. This includes but is not limited to oral or injectable anticoagulant treatments, anti-aggregant platelet treatment, chronic opioid analgesics. Low dose aspirin used for cardiovascular protection is allowed if a stable regimen is maintained for the duration of the study.
-
Subjects who had an oral, intramuscular, intravenous, rectal suppository or topical (excluded in index hip only) corticosteroid within 30 days of signing the ICF are excluded. Topical corticosteroid use at any site other than the index hip is allowed.
-
Significant trauma to the index hip within 26 weeks of screening
-
Chronic use of narcotics or cannabis.
-
Ligament instability or tear in index hip.
-
Diagnosis of fibromyalgia
-
Diagnosis of osteonecrosis in index hip
-
Subject has significant varus or valgus deformity greater than 10 degrees in either knee.
-
Subject requires consistent use of an assistive device (e.g. wheelchair, walker, etc.) Occasional use of a cane is acceptable.
-
Uncontrolled diabetes with HbA1c of >7%.
-
Subject is a woman who is pregnant or breastfeeding at the Screening Visit or a woman of child bearing potential who refuses to use effective contraception during the course of the study.
-
Subject is receiving or in litigation for worker's compensation.
-
Otherwise determined by the investigator to be medically unsuitable for participation in this study.
Baseline Exclusion Criteria
-
Subject has a decrease of ≥ 2 in the NRS pain on walking from Screening to Baseline in the index hip.
-
Subject has a contraindication to continue with the study treatment injection based on the visual appearance of the synovial fluid aspirate.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Krajská zdravotní, a.s. - Masarykova nemocnice Ústí nad Labem, o.z. | Ústí Nad Labem | Czechia | 401 13 | |
| 2 | NZOZ MEDI-SPATZ M.Spatz | Gliwice | Poland | 44-100 | |
| 3 | Przychodnia Rodzinna na Sadowej | Torun | Poland | 87-100 | |
| 4 | SPORTO sp. z o.o | Łódź | Poland | 90-038 |
Sponsors and Collaborators
- Anika Therapeutics, Inc.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Cingal 20-01